444 related articles for article (PubMed ID: 26891628)
1. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
[TBL] [Abstract][Full Text] [Related]
2. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
[TBL] [Abstract][Full Text] [Related]
3. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
4. L1CAM: amending the "low-risk" category in endometrial carcinoma.
Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
[TBL] [Abstract][Full Text] [Related]
5. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
Soovares P; Pasanen A; Bützow R; Lassus H
Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
[TBL] [Abstract][Full Text] [Related]
6. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
[TBL] [Abstract][Full Text] [Related]
7. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
Smogeli E; Davidson B; Cvancarova M; Holth A; Katz B; Risberg B; Kristensen G; Lindemann K
BMC Cancer; 2016 Aug; 16():596. PubMed ID: 27488577
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group.
Yoon H; Suh DH; Kim K; No JH; Kim YB; Kim H
Gynecol Oncol; 2024 May; 184():132-138. PubMed ID: 38309030
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
10. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
[TBL] [Abstract][Full Text] [Related]
11. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.
Kommoss S; Hartkopf AD; Krämer B; Bunz AK; Grevenkamp F; Kommoss F; Pasternak J; Arbabi SM; Wallwiener M; Staebler A; Lax SF; Brucker SY; Taran FA
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2183-2188. PubMed ID: 28710714
[TBL] [Abstract][Full Text] [Related]
12. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
Vagios S; Yiannou P; Giannikaki E; Doulgeraki T; Papadimitriou C; Rodolakis A; Nonni A; Vlachos A; Pavlakis K
Int J Clin Oncol; 2019 Nov; 24(11):1419-1428. PubMed ID: 31197557
[TBL] [Abstract][Full Text] [Related]
13. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
14. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
15. L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.
Klat J; Mladenka A; Dvorackova J; Bajsova S; Simetka O
Anticancer Res; 2019 Jan; 39(1):421-424. PubMed ID: 30591489
[TBL] [Abstract][Full Text] [Related]
16. Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker.
Pasanen A; Loukovaara M; Tuomi T; Bützow R
Int J Gynecol Cancer; 2017 Sep; 27(7):1318-1324. PubMed ID: 29059097
[TBL] [Abstract][Full Text] [Related]
17. Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis.
Geels YP; Pijnenborg JM; van den Berg-van Erp SH; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Obstet Gynecol; 2012 Nov; 120(5):1124-31. PubMed ID: 23090531
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
19. L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer.
Abdel Azim S; Sprung S; Mutz-Dehbalaie I; Fessler S; Zeimet AG; Marth C
Int J Gynecol Pathol; 2017 Jul; 36(4):356-363. PubMed ID: 28221216
[TBL] [Abstract][Full Text] [Related]
20. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
Visser NCM; van der Putten LJM; van Egerschot A; Van de Vijver KK; Santacana M; Bronsert P; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Krakstad C; Tangen IL; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Hausnerova J; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Trovik J; Amant F; Massuger LFAG; Bulten J; Pijnenborg JMA
Hum Pathol; 2019 Jul; 89():90-98. PubMed ID: 31054899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
